Clinical Trial Results:
Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate Crohn’s Disease
Summary
|
|
EudraCT number |
2014-001892-30 |
Trial protocol |
HU BE |
Global end of trial date |
09 Dec 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Oct 2020
|
First version publication date |
16 Oct 2020
|
Other versions |
|
Summary report(s) |
Cancelled before enrollment statement |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GLPG1205-CL-201
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Galapagos NV
|
||
Sponsor organisation address |
Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
|
||
Public contact |
Medical Information, Galapagos NV, +32 15342900, medicalinfo@glpg.com
|
||
Scientific contact |
Clinical Trial Information Desk, Galapagos NV, +32 15342900, rd@glpg.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Dec 2014
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Dec 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate efficacy in terms of the change in Crohn’s Disease Activity Index (CDAI) score compared with baseline following 12 weeks of treatment with GLPG1205 100 mg once daily (qd) versus placebo in subjects with active moderate Crohn’s Disease (CD).
|
||
Protection of trial subjects |
This study will be conducted in accordance with the current ICH-GCP Guideline E6. Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of study subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical study data are credible.
The investigator or designated personnel must explain the study and the implications of participation (e.g., objectives, methods, anticipated benefits, and possible risks) to potential subjects according to local regulations prior to any trial related activity. Subjects will be informed that their participation is voluntary and that they may withdraw from the study at any time. They will be informed that choosing not to participate or to withdraw from the study will not have an impact on the care the subject will receive for the treatment of his/her disease. In case the subject is unable to read and write, an impartial witness must confirm the informed consent.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Nov 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 99999
|
||
Worldwide total number of subjects |
99999
|
||
EEA total number of subjects |
99999
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
99999
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
99999 is "Not applicable" value or 0 participants, this trial was discontinued with no participants enrolled in the trial. | ||||||
Pre-assignment
|
|||||||
Screening details |
N/A | ||||||
Period 1
|
|||||||
Period 1 title |
Overall Trial (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
N/A
|
||||||
Arms
|
|||||||
Arm title
|
GLPG1205 | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
GLPG1205
|
||||||
Investigational medicinal product code |
G321605
|
||||||
Other name |
|||||||
Pharmaceutical forms |
Capsule
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Subjects will receive 100 mg GLPG1205 (2 capsules of 50 mg) or placebo qd for 12 weeks. The GLPG1205 or placebo capsules should be taken orally with a glass of water in the morning. Subjects will be instructed to swallow the study drug whole, and not chew the drug prior to swallowing.
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall Trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
GLPG1205
|
||
Reporting group description |
- |
|
|||||||||
End point title |
CDAI baseline score [1] | ||||||||
End point description |
Difference in CDAI change from baseline between GLPG1205- and placebo-treated subjects at Week 12.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
N/A
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No subjects were enrolled in the trial hence results are not available. |
|||||||||
|
|||||||||
Notes [2] - No subjects were enrolled in the trial hence results are not available. |
|||||||||
No statistical analyses for this end point |
|
|||||||||||
Adverse events information [1]
|
|||||||||||
Timeframe for reporting adverse events |
From first study drug administration until the last follow-up visit.
|
||||||||||
Assessment type |
Systematic | ||||||||||
Dictionary used for adverse event reporting
|
|||||||||||
Dictionary name |
MedDRA | ||||||||||
Dictionary version |
0
|
||||||||||
Reporting groups
|
|||||||||||
Reporting group title |
GLPG1205
|
||||||||||
Reporting group description |
GLPG1205 Dose A | ||||||||||
|
|||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||
|
|||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No subjects were enrolled in the trial hence results are not available . |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
99999 is "Not applicable" value or 0 participants, this trial was discontinued with no participants enrolled in the trial. |